Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immunodiagnostic Systems strengthens endocrinology offering with Diametra buy

This article was originally published in Clinica

Executive Summary

Immunodiagnostic Systems has acquired Italian immunoenzymatic assays specialist Diametra for an undisclosed fee, as it builds its presence in the specialty testing arena. In particular, the deal strengthens IDS’s endocrinology pipeline. Milan-based Diametra has around 25 employees, and in 2013 generated revenues of €3.3m ($4.3m) and earnings before interest and tax of €0.3m. As well as endocrinology, the company has a wide variety of tests covering areas including molecular biology, hypertension, autoimmune disease, diabetes monitoring, and tumor markers. The two firms already have a relationship, and for the past nine months have been collaborating to convert one of Diametra’s manual assays onto IDS’s fully automated IDS-iSYS instrument. IDS intends to convert several more of Diametra’s steroid hormone tests onto the IDS-iSYS. Diametra also gives IDS additional development and manufacturing capabilities.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT101905

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel